Abstract

Breast cancer (BC) has been extensively studied, as it is one of the more commonly diagnosed cancer types worldwide. The study of miRNAs has increased what is known about the complexity of pathways and signaling and has identified potential biomarkers and therapeutic targets. Thus, miRNome profiling could provide important information regarding the molecular mechanisms involved in BC. On average, more than 430 miRNAs were identified as differentially expressed between BC cell lines and normal breast HMEC cells. From these, 110 miRNAs were common to BC subtypes. The miRNome enrichment analysis and interaction maps highlighted epigenetic-related pathways shared by all BC cell lines and revealed potential miRNA targets. Quantitative evaluation of BC patient samples and GETx/TCGA-BRCA datasets confirmed MYB and EZH2 as potential targets from BC miRNome. Moreover, overall survival was impacted by EZH2 expression. The expression of 15 miRNAs, selected according to aggressiveness of BC subtypes, was confirmed in TCGA-BRCA dataset. Of these miRNAs, miRNA-mRNA interaction prediction revealed 7 novel or underexplored miRNAs in BC: miR-1271-5p, miR-130a-5p, and miR-134 as MYB regulators and miR-138-5p, miR-455-3p, miR-487a, and miR-487b as EZH2 regulators. Herein, we report a novel molecular miRNA signature for BC and identify potential miRNA/mRNAs involved in disease subtypes.

Highlights

  • Breast cancer (BC) is the most common type of cancer and the leading cause of cancer-related death among women worldwide

  • To obtain the miRNome profiles from the BC cell lines used in our study (MCF7, EVSA-T, HCC-1954 and MDA-MB-231), we performed a global analysis of the 1008 miRNAs in the miRNome PCR array

  • We identified 110 common differentially expressed miRNAs when comparing the BC cell lines analyzed in our study with the HMEC cell line

Read more

Summary

Introduction

Breast cancer (BC) is the most common type of cancer and the leading cause of cancer-related death among women worldwide. BC is classified according to the presence of receptors into 4 major molecular subtypes [1, 2]: luminal A (estrogen and/or progesterone receptor positive), luminal-HER (estrogen and/or progesterone receptor positive and HER2 positive), HER2 (human epidermal receptor 2 positive or enriched) and triple-negative (negative for these receptors) [3]. The carcinogenesis of BC is complex and involves several distinct mechanisms at the cellular and molecular levels. In addition to genetic alterations and microenvironment involvement, epigenetic modifications occur in tumor cell progression. These alterations in gene expression can be driven by different processes, such as methylation, histone modification, chromatin remodeling, and by noncoding RNAs, such as microRNAs (miRNAs) [4, 5]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call